{"id":3009,"date":"2026-05-08T18:08:00","date_gmt":"2026-05-08T16:08:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=66c97d7febd6d122dfbf61cbb11381bc"},"modified":"2026-05-08T18:08:00","modified_gmt":"2026-05-08T16:08:00","slug":"leniobio-and-twist-bioscience-enter-into-a-collaboration-to-further-enable-ai-drug-discovery","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=3009","title":{"rendered":"LenioBio and Twist Bioscience Enter into a Collaboration to Further Enable AI drug-discovery"},"content":{"rendered":"<p>D\u00dcSSELDORF, Germany--(BUSINESS WIRE)--LenioBio GmbH, a TechBio company commercializing its ALiCE\u00ae cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE\u00ae platform with Twist\u2019s DNA manufacturing and automation capabilities to accelerate the design\u2013build\u2013test cycle for protein expression services\u2014delivering experimental results back to customers\u2019 and partners\u2019 AI models faster.<\/p><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260508523530\/en\/2799008\/5\/LenioBio_Horizontal_RGB.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260508523530\/en\/2799008\/22\/LenioBio_Horizontal_RGB.jpg\" \/><\/a><br\/><a href=\"https:\/\/mms.businesswire.com\/media\/20260508523530\/en\/2799008\/5\/LenioBio_Horizontal_RGB.jpg\"><img src=\"https:\/\/mms.businesswire.com\/media\/20260508523530\/en\/2799008\/21\/LenioBio_Horizontal_RGB.jpg\" \/><\/a><p>\n\u201cAI can design new protein molecules for biologic drugs: the problem is that reality doesn\u2019t always reflect what the computer imagines,\u201d said Andr\u00e9 Goerke, CEO of LenioBio. \u201cBringing together Twist\u2019s highly automated manufacturing and characterization capabilities with LenioBio\u2019s ALiCE\u00ae system for cell-free protein expression, can enable rapid data generation from real-world molecules. The resulting data can then be fed back into the AI model as a tight lab-in-the-loop iteration\u2014so design decisions are driven by fresh experimental evidence, without waiting weeks for expression bottlenecks.\u201d<\/p><p>\n<b>Why this matters:<\/b> In AI-driven protein and antibody design, advantage comes from iteration speed and the quality of biology-native data. This collaboration will help teams run faster, higher-throughput lab-in-the-loop cycles with rapid, eukaryotic cell-free expression.<\/p><p>\nThe ALiCE\u00ae platform enables production of full-length, folded, functional proteins within 24 hours\u2014compressing timelines versus traditional cell-based systems and reducing the latency between computational design and wet-lab validation. Compared to other cell-free systems, ALiCE\u00ae supports complex molecules with eukaryotic characteristics that are difficult to produce in alternative platforms. By implementing ALiCE\u00ae, Twist will expand and complement its existing protein expression capabilities.<\/p><p>\n\u201cAI-led antibody development is one of the most exciting growth areas in biologics where speed of iteration and quality of experimental readouts directly shape model performance and decision-making,\u201d said Emily M. Leproust, CEO and co-founder of Twist Bioscience. \u201cTo enable our customers working in AI-enabled drug discovery, we built out our characterization offering and now we\u2019re continuing to expand it. Through this collaboration with LenioBio, we will be able to add cell-free protein expression to our offering.\u201d<\/p><br\/> <b>Contacts<\/b> <br\/><p>\nDr Desmond Schofield\n<br\/>Head of Business Development\n<br\/>+44-7485-788-543\n<br\/><a  href=\"mailto:d.schofield@leniobio.com\" rel=\"nofollow\" shape=\"rect\">d.schofield@leniobio.com<\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>D\u00dcSSELDORF, Germany&#8211;(BUSINESS WIRE)&#8211;LenioBio GmbH, a TechBio company commercializing its ALiCE\u00ae cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our A&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-3009","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/3009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3009"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/3009\/revisions"}],"predecessor-version":[{"id":3010,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/3009\/revisions\/3010"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}